PTX Price sensitive 27 May 2025, 9:07 AM

First Patient dosed for PTX-100 Phase 2a Study

Prescient Therapeutics Ltd

No summary is available for this announcement — sign in to read the PDF in full.

Sign in for more about this company, including guidance changes and other insights.
Sign in